Valuation: Immatics N.V.

Market Cap 1.22B 1.05B 978M 895M 1.68B 117B 1.7B 11.57B 4.5B 58.66B 4.58B 4.48B 194B P/E 2026 *
-4.18x
P/E 2027 * -4.17x
Enterprise Value 1.02B 870M 814M 745M 1.4B 97.21B 1.42B 9.63B 3.75B 48.83B 3.81B 3.73B 162B EV / Sales 2026 *
21.8x
EV / Sales 2027 * 23.7x
Free-Float
74.81%
Yield 2026 *
-
Yield 2027 * -
1 day+4.44%
1 week-5.40%
Current month+3.12%
1 month-3.88%
3 months-23.15%
6 months-9.80%
Current year-14.95%
1 week 8.4
Extreme 8.4
9.31
1 month 8.17
Extreme 8.17
9.98
Current year 8.17
Extreme 8.17
11.94
1 year 5.05
Extreme 5.05
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
16.3
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 2018-12-31
Director of Finance/CFO 57 2025-09-30
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 51 2020-06-30
Chairman 70 2012-09-30
Director/Board Member 72 2020-06-30
Date Insider Type Main position Quantity % Market Cap.
3/17/26 Other

Director

436,021 0.3252%
6/9/20
Arya Sciences Holdings
OthersCompany 499,000 3.4713%
Change 5-day change 1-year change 3-year change Capi.($)
+4.44%-5.40%+56.94%-27.69% 1.22B
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.94% 65.85B
+5.12%+25.22%+5.13%-5.23% 29.28B
+0.55%+1.64%-4.63%+469.35% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+148.64% 13.4B
Average +1.57%+6.99%+58.88%+173.75% 29.07B
Weighted average by Cap. +0.76%+9.42%+58.02%+155.93%

Financials

2026 *2027 *
Net sales 46.51M 39.83M 37.26M 34.08M 64.17M 4.45B 64.88M 441M 172M 2.23B 175M 171M 7.39B 39.54M 33.86M 31.68M 28.98M 54.56M 3.78B 55.16M 375M 146M 1.9B 148M 145M 6.29B
Net income -287M -246M -230M -210M -396M -27.46B -400M -2.72B -1.06B -13.79B -1.08B -1.05B -45.63B -310M -265M -248M -227M -427M -29.64B -432M -2.94B -1.14B -14.89B -1.16B -1.14B -49.24B
Net Debt -205M -175M -164M -150M -282M -19.58B -285M -1.94B -755M -9.83B -768M -751M -32.53B -283M -243M -227M -208M -391M -27.09B -395M -2.68B -1.04B -13.61B -1.06B -1.04B -45.02B
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
678
Date Price Change Volume
26-08-21 $8.930 +4.44% 611,317
26-08-20 $8.550 -7.57% 474,772
26-08-19 $9.250 +1.76% 593,319
26-08-18 $9.090 -1.73% 995,017
26-08-17 $9.250 -2.01% 1,067,846
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
8.930USD
Average target price
17.80USD
Spread / Average Target
+99.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock